Limits...
Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.

Prager GW, Braemswig KH, Martel A, Unseld M, Heinze G, Brodowicz T, Scheithauer W, Kornek G, Zielinski CC - Cancer Sci. (2014)

Bottom Line: Patients with baseline CEA serum levels below the statistical median of 26.8 ng/mL (group I) were compared with patients with higher CEA levels (group II).The cetuximab-based treatment cohort was analyzed for specificity assessment of CEA to predict the anti-vascular endothelial growth factor effect in mCRC.In an independent cohort of 129 patients treated with cetuximab-based therapy, no association of therapeutic response or PFS with CEA serum levels was found.

View Article: PubMed Central - PubMed

Affiliation: Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Austria.

Show MeSH

Related in: MedlinePlus

Carcinoembryonic antigen (CEA) serum levels and treatment response in patients with metastatic colorectal cancer receiving bevacizumab-based therapies. Disease control was defined as complete remission, partial remission, or stable disease.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317865&req=5

fig01: Carcinoembryonic antigen (CEA) serum levels and treatment response in patients with metastatic colorectal cancer receiving bevacizumab-based therapies. Disease control was defined as complete remission, partial remission, or stable disease.

Mentions: The DC assessed according to RECIST criteria in bevacizumab-treated patients correlated with CEA serum levels: DC occurred in 71 (84%) of the 85 patients in group I, and in 50 (60%) of the 84 patients in group II (χ2-test, i < 0.005: odds ratio, 0.579; 95% CI, 0.422–0.795; P < 0.001) (Fig. 1).


Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.

Prager GW, Braemswig KH, Martel A, Unseld M, Heinze G, Brodowicz T, Scheithauer W, Kornek G, Zielinski CC - Cancer Sci. (2014)

Carcinoembryonic antigen (CEA) serum levels and treatment response in patients with metastatic colorectal cancer receiving bevacizumab-based therapies. Disease control was defined as complete remission, partial remission, or stable disease.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317865&req=5

fig01: Carcinoembryonic antigen (CEA) serum levels and treatment response in patients with metastatic colorectal cancer receiving bevacizumab-based therapies. Disease control was defined as complete remission, partial remission, or stable disease.
Mentions: The DC assessed according to RECIST criteria in bevacizumab-treated patients correlated with CEA serum levels: DC occurred in 71 (84%) of the 85 patients in group I, and in 50 (60%) of the 84 patients in group II (χ2-test, i < 0.005: odds ratio, 0.579; 95% CI, 0.422–0.795; P < 0.001) (Fig. 1).

Bottom Line: Patients with baseline CEA serum levels below the statistical median of 26.8 ng/mL (group I) were compared with patients with higher CEA levels (group II).The cetuximab-based treatment cohort was analyzed for specificity assessment of CEA to predict the anti-vascular endothelial growth factor effect in mCRC.In an independent cohort of 129 patients treated with cetuximab-based therapy, no association of therapeutic response or PFS with CEA serum levels was found.

View Article: PubMed Central - PubMed

Affiliation: Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Austria.

Show MeSH
Related in: MedlinePlus